Blocking METTL3-mediated lncRNA FENDRR silence reverses cisplatin resistance of lung adenocarcinoma through activating TFRC-mediated ferroptosis pathway
Journal of Molecular Histology · 2025
DOI: 10.1007/s10735-024-10276-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Histology, 2025. Verfasst von Peng Zhao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Affiliated Hospital of Hebei Engineering University, No. 81 Congtai Road, Congtai District, Handan, 056000, Hebei, Ch…. Hauptthemen laut MEDLINE: Ferroptosis, Cisplatin, Drug Resistance, Neoplasm, Methyltransferases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Handan Science and Technology Research and Development Plan Project.
Abstract (Originalsprache)
Targeting ferroptosis pathway becomes a new solution for cisplatin (DDP) resistance in lung adenocarcinoma (LUAD), and further research is required to explore the molecular mechanisms underlying ferroptosis and DDP resistance, providing biotargets for LUAD treatment. In this study, DDP-sensitive A549 cells and DDP-resistant A549/DDP cells were treated with DDP, DDP sensitivity was detected through using CCK-8 method and colony formation assay, ferroptosis-related markers were determined through commercial kits, and the molecular regulatory mechanism was analyzed through methylated RNA immunoprecipitation, RNA pull-down, dual luciferase assay, quantitative real-time polymerase chain reaction and western blotting assay. Results showed that compared to A549 cells, FENDRR was downregulated in A549/DDP cells, and FENDRR increased iron content, labile iron pool, lipid peroxidation, LDH release and ROS levels, accelerating ferroptosis to promote DDP sensitivity. Interestingly, we found that METTL3-mediated N6-methyladenosine modification YTHDF2 dependently resulted in FENDRR degradation, and FENDRR overexpression elevated TFRC expression through sponging miR-761. Mechanistically, METTL3 inhibited the FENDRR/TFRC axis to alleviate DDP-induced ferroptosis, promoting DDP resistance in LUAD cells. Collectively, our findings identify a novel molecular regulatory mechanism in DDP resistance of LUAD, and suggest that FENDRR might be an attractive target for addressing DDP resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Affiliated Hospital of Hebei Engineering University, No. 81 Congtai Road, Congtai District, Handan, 056000, Hebei, China.
- Oncology Department, Shexian Hospital, Handan, 056400, China.
- Department of Cardiac Surgery, Affiliated Hospital of Hebei Engineering University, Handan, 056000, China.
- Department of Thoracic Surgery, Affiliated Hospital of Hebei Engineering University, No. 81 Congtai Road, Congtai District, Handan, 056000, Hebei, China. 18031022655@163.com.
Förderung
- Handan Science and Technology Research and Development Plan Project
Zitieren
APA
Zhao, P., Ren, X., Zhang, Z., Duan, Z., Yang, X., Jin, J., & Hu, J. (2025). Blocking METTL3-mediated lncRNA FENDRR silence reverses cisplatin resistance of lung adenocarcinoma through activating TFRC-mediated ferroptosis pathway. Journal of Molecular Histology. https://doi.org/10.1007/s10735-024-10276-4
Vancouver
Zhao P, Ren X, Zhang Z, Duan Z, Yang X, Jin J, et al. Blocking METTL3-mediated lncRNA FENDRR silence reverses cisplatin resistance of lung adenocarcinoma through activating TFRC-mediated ferroptosis pathway. Journal of Molecular Histology. 2025. doi:10.1007/s10735-024-10276-4
BibTeX
@article{Zhao2025,
author = {Zhao, Peng and Ren, Xiaoguo and Zhang, Zhenchao and Duan, Zhentao and Yang, Xiaogang and Jin, Jiatai and Hu, Jigang},
title = {Blocking METTL3-mediated lncRNA FENDRR silence reverses cisplatin resistance of lung adenocarcinoma through activating TFRC-mediated ferroptosis pathway},
journal = {Journal of Molecular Histology},
year = {2025},
doi = {10.1007/s10735-024-10276-4}
}
EUVIMED